JP Morgan Chase’s Arbutus Biopharma ABUS Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2019
Q2
– Sell
-129,000
Closed -$462K – 5739
2019
Q1
$462K Buy
129,000
+54,000
+72% +$207K ﹤0.01% 4247
2018
Q4
$287K Sell
75,000
-67,000
-47% -$330K ﹤0.01% 4418
2018
Q3
$1.34M Buy
+142,000
New +$1.41M ﹤0.01% 3725

Other funds holding ABUS

JP Morgan Chase's ABUS Position: Q3 2026 in Review

JP Morgan Chase increased its Arbutus Biopharma (ABUS) stake by 13% in Q3 2026, buying an estimated $59.3K and bringing the position to 110,521 shares worth $518K. The position accounts for ﹤0.01% of the portfolio, ranked #5193.

JP Morgan Chase first reported a position in ABUS in Q2 2015 and has held it in 39 quarters since. The position peaked at $2.93M in Q4 2024. 214 funds tracked by Wall St. Rank hold ABUS as of Q3 2026.

  • JP Morgan Chase held 110,521 shares of Arbutus Biopharma worth $518K as of Q3 2026.
  • JP Morgan Chase bought 12,297 Arbutus Biopharma shares in Q3 2026, an estimated $59.3K.
  • Arbutus Biopharma made up ﹤0.01% of JP Morgan Chase's portfolio in Q3 2026, its #5193 holding.
  • JP Morgan Chase first reported a position in Arbutus Biopharma in Q2 2015 and has held it in 39 quarters since.
  • JP Morgan Chase's Arbutus Biopharma position peaked at $2.93M in Q4 2024.
  • 214 funds tracked by Wall St. Rank held Arbutus Biopharma as of Q3 2026.

Based on JP Morgan Chase's 13F filing for Q3 2026, filed 12 Nov 2026.